Biomark Diagnostics Stock Analysis
| BMKDF Stock | USD 0.24 0.02 7.69% |
BioMark Diagnostics is overvalued with Real Value of 0.19 and Hype Value of 0.24. The main objective of BioMark Diagnostics otc analysis is to determine its intrinsic value, which is an estimate of what BioMark Diagnostics is worth, separate from its market price. There are two main types of BioMark Diagnostics' stock analysis: fundamental analysis and technical analysis.
The BioMark Diagnostics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and BioMark Diagnostics' ongoing operational relationships across important fundamental and technical indicators.
BioMark |
BioMark OTC Stock Analysis Notes
About 55.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.01. BioMark Diagnostics had not issued any dividends in recent years. BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.The quote for BioMark Diagnostics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. For more info on BioMark Diagnostics please contact the company at 604 370 0779 or go to https://www.biomarkdiagnostics.com.BioMark Diagnostics Investment Alerts
| BioMark Diagnostics is way too risky over 90 days horizon | |
| BioMark Diagnostics has some characteristics of a very speculative penny stock | |
| BioMark Diagnostics appears to be risky and price may revert if volatility continues | |
| BioMark Diagnostics has accumulated 96.3 K in total debt. BioMark Diagnostics has a current ratio of 0.34, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist BioMark Diagnostics until it has trouble settling it off, either with new capital or with free cash flow. So, BioMark Diagnostics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioMark Diagnostics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioMark to invest in growth at high rates of return. When we think about BioMark Diagnostics' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 43.93 K. Net Loss for the year was (1.45 M) with profit before overhead, payroll, taxes, and interest of 43.93 K. | |
| BioMark Diagnostics has accumulated about 364.96 K in cash with (1.2 M) of positive cash flow from operations. | |
| Roughly 55.0% of the company shares are held by company insiders |
BioMark Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.74 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate BioMark Diagnostics's market, we take the total number of its shares issued and multiply it by BioMark Diagnostics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 21st of July, BioMark Diagnostics shows the Mean Deviation of 2.98, risk adjusted performance of 0.12, and Downside Deviation of 7.75. BioMark Diagnostics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down nineteen technical drivers for BioMark Diagnostics, which can be compared to its peers. Please confirm BioMark Diagnostics information ratio and the relationship between the maximum drawdown and skewness to decide if BioMark Diagnostics is priced correctly, providing market reflects its regular price of 0.24 per share. As BioMark Diagnostics appears to be a penny stock we also recommend to validate its total risk alpha numbers.BioMark Diagnostics Price Movement Analysis
The output start index for this execution was twenty-nine with a total number of output elements of thirty-two. The Simple Moving Average indicator is calculated by adding the closing price of BioMark Diagnostics for a given number of time periods and then dividing this total by the number of time periods. It is used to smooth out BioMark Diagnostics short-term fluctuations and highlight longer-term trends or cycles.
BioMark Diagnostics Predictive Daily Indicators
BioMark Diagnostics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioMark Diagnostics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.92 | |||
| Day Median Price | 0.24 | |||
| Day Typical Price | 0.24 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.02) |
BioMark Diagnostics Forecast Models
BioMark Diagnostics' time-series forecasting models are one of many BioMark Diagnostics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioMark Diagnostics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About BioMark OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how BioMark Diagnostics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioMark shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as BioMark Diagnostics. By using and applying BioMark OTC Stock analysis, traders can create a robust methodology for identifying BioMark entry and exit points for their positions.
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc. Biomark Diagnostics operates under Diagnostics Research classification in the United States and is traded on OTC Exchange.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding BioMark Diagnostics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Alpha Finder Now
Alpha FinderUse alpha and beta coefficients to find investment opportunities after accounting for the risk |
| All Next | Launch Module |
Complementary Tools for BioMark OTC Stock analysis
When running BioMark Diagnostics' price analysis, check to measure BioMark Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioMark Diagnostics is operating at the current time. Most of BioMark Diagnostics' value examination focuses on studying past and present price action to predict the probability of BioMark Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioMark Diagnostics' price. Additionally, you may evaluate how the addition of BioMark Diagnostics to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |